主要研究目的：按有关生物等效性试验的规定，选择Les Laboratoires Servier为持证商的培哚普利氨氯地平片（III）（商品名：开素达，规格：每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）5mg）为参比制剂，对石家庄四药有限公司生产的受试制剂培哚普利氨氯地平片（III）（规格：每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）5mg）进行空腹和餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹和餐后给药条件下的生物等效性。次要研究目的：观察健康志愿受试者口服受试制剂培哚普利氨氯地平片（III）（规格：每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）5mg）和参比制剂培哚普利氨氯地平片（III）（商品名：开素达，规格：每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）5mg）的安全性。

开始日期2024-05-11

申办/合作机构

石家庄四药有限公司

CTR20240656 / CompletedN/A

培哚普利氨氯地平片（Ⅰ）生物等效性试验

主要研究目的研究空腹和餐后状态下单次口服受试制剂培哚普利氨氯地平片（Ⅰ）（规格：每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）10mg，杭州和泽坤元药业有限公司提供）与参比制剂培哚普利氨氯地平片（Ⅰ）（COVERAM®，规格：每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）10mg，持证商：Les Laboratoires Servier），在健康成年受试者体内的药代动力学，评价空腹和餐后口服两种制剂的生物等效性。次要研究目的评价中国健康受试者空腹和餐后状态下，单次口服受试制剂培哚普利氨氯地平片（Ⅰ）和参比制剂培哚普利氨氯地平片（Ⅰ）（COVERAM®）后的安全性。

开始日期2024-03-12

申办/合作机构

杭州和泽坤元药业有限公司

CTR20234196 / CompletedN/A

培哚普利氨氯地平片(III)在空腹及餐后条件下的人体生物等效性试验

考察空腹及餐后条件下，健康受试者单次口服桂林华信制药有限公司生产的培哚普利氨氯地平片（Ⅲ）【受试制剂T，规格：每片含精氨酸培哚普利10mg和苯磺酸氨氯地平（以氨氯地平计）5mg】或Les Laboratoires Servier 持证的培哚普利氨氯地平片（Ⅲ）【参比制剂R，商品名：开素达®，规格：每片含精氨酸培哚普利10mg 和苯磺酸氨氯地平（以氨氯地平计）5mg】的药动学特征，评价两制剂间的生物等效性和安全性，为受试制剂的注册申请提供依据。

开始日期2024-01-14

申办/合作机构

桂林华信制药有限公司

100 项与苯磺酸氨氯地平/精氨酸培哚普利相关的临床结果

登录后查看更多信息

100 项与苯磺酸氨氯地平/精氨酸培哚普利相关的转化医学

登录后查看更多信息

100 项与苯磺酸氨氯地平/精氨酸培哚普利相关的专利（医药）

登录后查看更多信息

934

项与苯磺酸氨氯地平/精氨酸培哚普利相关的文献（医药）

2024-05-01·Journal of dairy science

A dairy-based, protein-rich breakfast enhances satiety and cognitive concentration before lunch in overweight to obese young females: A randomized controlled crossover study

Article

作者: Norup, K ; Andersen, B V ; Kruse, D Z ; Dalgaard, L B ; Hansen, M

The purpose of this study was to investigate if consumption of a high-protein, low-carbohydrate breakfast (PRO) leads to a lower subsequent ad libitum energy intake at lunch and the rest of the day compared with ingestion of an isocaloric low-protein, high-carbohydrate breakfast (CHO) or no breakfast (CON). The study was designed as a randomized controlled 3-period crossover study. Thirty young (18-30 yr) females with overweight to obesity (body mass index >25 kg/m²) in random order completed 3 separate experimental days where they consumed either a PRO, CHO, or CON breakfast test meal followed by an ad libitum lunch meal 3 h after breakfast. Participants were allocated to a sequence group by their inclusion number. The PRO and CHO breakfasts were matched in dietary fiber and fat content. Energy intake at lunch was calculated and dietary records were obtained for the rest of the day to calculate the total daily energy intake and macronutrient intake. Ratings of appetite sensations between meals and palatability of the test meals were assessed using visual analog scale sheets in intervals ranging from 10 to 30 min. In addition, blood samples were obtained at multiple time points separated by 10 to 60 min intervals between breakfast and lunch and were analyzed for appetite-regulating gut hormones, insulin, and glucose. Finally, performance in a cognitive concentration test was tested 150 min after breakfast. Compared with CHO and CON, the area under the curves for satiety, fullness, and satisfaction in the 3 h after breakfast were significantly higher after PRO, whereas the areas under the curve for hunger, desire to eat, and prospective eating were significantly lower after PRO. The appetite-regulating gut hormones cholecystokinin, glucagon-like peptide-1, and ghrelin in the hours after breakfast, energy intake during the ad libitum lunch meal, and the total daily energy intake did not differ significantly between PRO, CHO, and CON. However, the cognitive concentration test score was 3.5 percentage points higher for PRO, but not CHO, versus CON. A dairy-based high-protein, low-carbohydrate breakfast increased satiety sensation in the hours after breakfast but did not reduce total daily energy intake compared with an isocaloric low-protein, high-carbohydrate breakfast or omitting breakfast. However, performance in a cognitive concentration test before lunch was enhanced after the high-protein, low-carbohydrate breakfast, but not the low-protein, high-carbohydrate breakfast, compared with omitting breakfast.

2024-03-01·Animal bioscience

Amino acid supplementation during the adaptation period did not affect the standardized ileal digestibility of amino acids in corn and soybean meal fed to pigs

Article

作者: Kim, Beob Gyun ; You, Sun Jong ; Choi, Hyunjun

Objective: The objective was to determine the influence of amino acid (AA) supplementation during the adaptation period on the ileal digestibility of crude protein and AA in corn and soybean meal (SBM) fed to pigs.Methods: Six barrows with an initial body weight of 30.9±2.6 kg fitted with a T-cannula at the distal ileum were assigned to a 6×6 Latin square design with 6 dietary treatments and 6 periods. Two experimental diets contained corn or SBM as the sole AA source and an N-free diet was additionally prepared. For AA supplementation groups, an AA mixture consisted of Gly, Lys, Met, Thr, Trp, Ile, Val, His, and Phe was added to the corn diet and the N-free diet at the expense of cornstarch, and an AA mixture of Lys, Met, and Thr was added to the SBM diet. All diets contained 0.5% of chromic oxide. The 6 experimental diets were fed to the pigs for four and half days, and the 3 diets containing an AA mixture were switched to the respective diets without AA mixture during the following two and half days. Ileal digesta were collected on days 6 and 7.Results: The addition of an AA mixture during the adaptation period increased apparent ileal digestibility of Arg and Trp in corn (p<0.05) but did not affect that in SBM. The addition of an AA mixture during the adaptation period increased apparent ileal digestibility of Pro and Gly regardless of feed ingredient (p<0.05) but did not affect that of other AA. All AA except Pro in corn and SBM were unaffected by the addition of the AA mixture during the adaptation period.Conclusion: The addition of amino acids to a low-protein diet during the adaptation period does not affect the standardized ileal digestibility of indispensable amino acids in pigs.

2024-02-01·Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Effects of natural antimicrobial compounds propolis and copaiba on periodontal ligament fibroblasts, molecular docking, and in vivo study in Galleria mellonella

Article

作者: Garcia, Maíra Terra ; Pedrinha, Victor Feliz ; Sipert, Carla Renata ; Shahbazi, Mohammad-Ali ; de Andrade, Flaviana Bombarda ; Queiroga, Carmen Lucia ; Lameira, Osmar Alves ; Junqueira, Juliana Campos ; Santos, Letícia Martins ; Gonçalves, Carolina Passarelli ; Marcucci, Maria Cristina ; Sharma, Prashant Kumar

Root canal treatment addresses infectious processes that require control. Occasionally, the radicular pulp is vital and inflamed, presenting a superficial infection. To preserve pulpal remnants, conservative procedures have gained favor, employing anti-inflammatory medications. This study investigated the effects of propolis (PRO), and copaiba oil-resin (COR) associated with hydrocortisone (H) and compared their impact to that of Otosporin® concerning cytotoxic and genotoxic activity, cytokine detection, and toxicity in the Galleria mellonella model. Human periodontal ligament fibroblasts (PDLFs) were exposed to drug concentrations and evaluated by the MTT assay. Associations were tested from concentrations that did not compromise cell density. Genotoxicity was evaluated through micronucleus counting, while cytokines IL-6 and TGF-β1 were detected in the cell supernatant using ELISA. Molecular docking simulations were conducted, considering the major compounds identified in PRO, COR, and H. Increasing concentrations of PRO and COR were assessed for acute toxicity in Galleria mellonella model. Cellular assays were analyzed using one-way ANOVA followed by Tukey tests, while larval survivals were evaluated using the Log-rank (Mantel-Cox) test (α = 0.05). PRO and COR promoted PDLFs proliferation, even in conjunction with H. No changes in cell metabolism were observed concerning cytokine levels. The tested materials induce the release of AT₁R, proliferating the PDFLs through interactions. PRO and COR had low toxicity in larvae, suggesting safety at tested levels. These findings endorse the potential of PRO and COR in endodontics and present promising applications across medical domains, such as preventive strategies in inflammation, shedding light on their potential development into commercially available drugs.

项与苯磺酸氨氯地平/精氨酸培哚普利相关的新闻（医药）

2024-02-24

·药智网

未来5年，10款重磅炸弹药物的关键专利到期

专利保护是一款药物甚至一家企业赖以持续性发展的关键武器，这一点在艾伯维的修美乐身上体现得最为明显。未来5年，将有多款重磅炸弹级药物的关键专利到期，这将为制药行业，尤其是仿制药和生物类似药开发商带来巨大的商机。以下是10款未来5年关键专利到期的重磅炸弹，它们在2023年的总销售额超过了800亿美元。表1 未来5年，关键专利到期的10款重磅炸弹药物数据来源：综合各家企业财报注意：第八个药品的销售额为Prevnar 13和Prevnar 20的共同销售额。01Keytruda有效成分：Pembrolizumab开发商：默沙东适应症：三阴性乳腺癌、黑色素瘤、非小细胞肺癌、头颈鳞状细胞癌、尿路上皮癌、结肠癌或直肠癌。2023年销售：250亿美元关键专利到期：2028年Keytruda于2014年首次获得FDA批准用于治疗多种类型的癌症。自获得最初批准以来，Keytruda的获批适应症不断增加，包括了黑色素瘤、非小细胞肺癌、头颈癌等。2023年，Keytruda占默沙东药品销售额的40%，这款新药王也成为默沙东最成功的产品。Keytruda预计将于2028年失去专利保护，为生物类似药竞争打开大门。Keytruda的销售额预计将在2029年降至274亿美元，比预计的2028年337亿美元销售额下降19%。为了抵消收入的大幅下降，默沙东正在准备通过建立早期资产管道来加强其免疫治疗产品组合。除此之外，默沙东于2024年初达成最终协议，以6.8亿美元收购Harpoon Therapeutics，这将进一步推进其肿瘤学产品组合。02Eliquis有效成分：Apixaban开发商：百时美施贵宝和辉瑞适应症：降低心律失常患者中风或血栓的风险关键专利到期时间：2027年至2029年2023年销售额：122亿美元Eliquis是一种用于预防成人血栓的药物。Eliquis最初于2011年5月在欧盟获得批准，并于2012年12月在美国获得批准，已成为深静脉血栓（Deep Vein Thrombosis）和肺栓塞（Pulmonary Embolism）最有效的治疗选择之一。Eliquis是心血管疾病领域2023年销售额排名榜第一的药物（122亿美元），远高于第二位的诺华的Entresto（58亿美元）。预计Eliquis将一直保持这一桂冠至2028年。随着Eliquis的专利将在未来几年内到期，百时美施贵宝和辉瑞公司的Eliquis的仿制药已经获得FDA的临时批准。由于和解外加一项关键诉讼，这两家制药巨头至少能在2027年之前守住Eliquis的市场阵地。目前尚不清楚Eliquis仿制药具体何时能够进入市场，但应该不会早于2027年。FDA授予了Eliquis儿科使用的延申，这将为其延长六个月的市场独占期。03Eylea有效成分：Aflibercept开发商：再生元、拜耳适应症：湿性年龄相关性黄斑变性等眼部疾病关键专利到期时间：2025年至2026年2023年销售额：58.86亿美元（美国）Eylea于2011年获得FDA批准用于治疗湿性年龄相关性黄斑变性、糖尿病性视网膜病变以及糖尿病性和非糖尿病性黄斑水肿。2023年，Eylea特许经营在美国的销售额达到59亿美元。专家预计Eylea的专利将于2025年或2026年结束，尽管Regeneron向投资人宣称，他们的市场独占期可能会更长。与此同时，Sandoz和Viatris等大型制药公司已经瞄准了市场份额，积极开发生物类似药并抢占市场。04Opdivo有效成分：nivolumab公司：百时美施贵宝适应症：多种癌症关键专利到期：2028年2023年销售额：90.09亿美元百时美施贵宝的Opdivo（nivolumab）是一种免疫疗法，用于治疗多种不同的癌症，是当今药王Keytruda的直接竞争对手。虽然销售额上不及Keytuda的一半，但也在2023年实现了90.09亿的销售业绩，称得上是巨型重磅炸弹。得益于一些新的适应症的获批，Opdivo在过去几年中出现了令人印象深刻的增长，销售额2023年增长9%，预计到2026年销售额将达到117.5亿美元。但BMS将在2028年失去Opdivo的美国市场独占权。总部位于悉尼的NeuClone Pharmaceuticals、瑞典公司Xbrane Biopharma和中国绿叶制药已经在致力于开发nivolumab生物类似药。未来几年内有好几款巨型重磅炸弹药物的专利到期都涉及BMS，除了Opdivo之外，癌症药物Revlimid和辉瑞合作的血液稀释剂Eliquis的独家经营权都将面临丧失。BMS目前正在努力推出六种新药，这些药物合计可能贡献超过150亿美元的销售额。05Ibrance有效成分：Palbociclib适应症：HR阳性和HER2阴性乳腺癌开发商：辉瑞关键专利到期：2027年2023年销售额：47.53亿美元尽管辉瑞预计他们的抗肿瘤药物Ibrance在2027年之前不会失去美国市场独占权，但这并不能阻止仿制药公司开发各自的Palbociclib仿制药。2019年已有多家仿制药制造商通知辉瑞，他们已向FDA递交了Ibrance仿制药的申请。尽管他们的理由是认为Ibrance的两项关键专利无效，但辉瑞还是成功获得了4年延期，直至2027年。实际上，Ibrance的销售额在2023年已经出现了下降，从一年前的51.2亿美元下降到了47.53亿美元，这主要是由于竞争压力和某些国际市场的临床试验采购减少导致全球需求下降。由于Ibrance的未来充满不确定性，过去几年，辉瑞一直在努力增强其肿瘤产品组合，包括收购Array BioPharma、Seagen和Trillium Therapeutics的交易。06Xarelto有效成分：Rivaroxaban适应症：血栓公司：拜耳/强生关键专利到期：2026年2023年销售额：23.65亿美元Xarelto（Rivaroxaban）于2007年获得专利，并于2011年在美国批准用于医疗用途，用于治疗和预防血栓。这种抗凝剂由拜耳和强生旗下杨森制药公司联合开发，仅在美国就已被开出超过8000万次处方。2022年，它是拜耳最畅销的药品，带来了价值45.16亿欧元的收入。预计拜耳将在2026年失去Xarelto的独占权。而在美国市场，Lupin的Rivaroxaban仿制药（RLD Xarelto）已经收到了FDA的暂定批准，正在积极准备将其仿制药推向市场。随着Xarelto和Eylea两大明星产品即将到期，拜耳一直在寻找新的增长机会，并专注于进一步扩大其在细胞和基因治疗领域的开发组合。07Trulicity有效成分：dulaglutide开发商：礼来适应症：2型糖尿病关键专利到期：2027年2023年销售额：70亿美元Trulicity为注射剂型，用于治疗成人和10岁以上儿童的2型糖尿病。Trulicity于2014年获得批准，其有效成分daluglutide的专利保护将于2027年到期，届时将为仿制药商是让开道路。Trulicity在2023年成为全球第17位最畅销药物。在推出了tirzepatide灌装的Mounjaro和Zepbound之后，trulicity的逐渐式微带给礼来的冲击将会被顺利化解。08Prevnar 13开发商：辉瑞适应症：肺炎链球菌菌株引起的感染关键专利到期：2026年2023年销售额：64亿美元（Prevnar 13/20的共同销售额）辉瑞公司的Prevnar 13是一种疫苗，用于预防13种肺炎链球菌菌株引起的感染，这些细菌可导致肺炎、脑膜炎和其他严重疾病。Prevnar 13接种于2009年底在欧洲首次用于婴儿，随后于2010年2月获得FDA批准。2015年，美国联邦政府推荐该疫苗用于65岁以上的人群，这为辉瑞带来了巨大的利润。Prevnar 13的专利预计将于2026年到期。为了弥补Prevnar 13专利到期导致的损失，辉瑞在研发方面投入巨资，并在2023年获得了7项FDA批准，并通过2023年12月收购Seagen Inc来加强其肿瘤产品组合。09Ocrevus有效成分：Ocrelizumab开发商：罗氏适应症：复发性或早期原发性进行性多发性硬化症关键专利到期：2028年2023年销售额：63.81亿瑞士法郎（72.46亿美元）罗氏的复发性或早期原发性进行性多发性硬化症药物Ocrevus（Ocrelizumab）是他们2023年销售量第二的资产，收获了63.81亿瑞士法郎（72.46亿美元）的销售额。Ocrevus在美国专利预计将于2029年到期，德国、法国、西班牙、英国和意大利的专利也将于2028年到期。许多生命科学公司都在竞相开发Ocrelizumab的生物类似药，其中包括韩国生物制药公司Celltrion，该公司于2023年宣布已获得3期批准。罗氏仍然专注于内部开发，最近宣布其新的乳腺癌治疗药物inavolisib取得了非常有希望的结果。他们还在项目和企业并购方面加大投入，强化他们在炎症性肠病和心脏代谢疾病等领域的投资组合。10Prolia/Xgevav有效成分：Denosumab开发商：安进适应症：继发性骨癌关键专利到期：2025年至2026年2023年销售额：40.48亿美元（Prolia），21.11亿美元（Xgeva）Prolia/Xgeva(Denosumab)于2010年获得FDA批准，是继发性骨癌的治疗药物。在欧洲的一些地区，Prolia/Xgeva已经失去了专利保护，其在美国、法国、意大利、西班牙和英国等主要市场的专利保护将于2025年至2026年间到期。Ref.1.Burke,H.Top 10 drugs with patents due to expire in the next five years.Proclinical.16.02.2024.2.Elmhirst,E.Eliquis:the cardio drug that cannot be beat.3.Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023.BMS Press Release.02.02.2024.4.Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance.Pfizer Press Release.30.01.2024.5.Lupin Receives Tentative Approval from U.S.FDA for Rivaroxaban Tablets USP.Lupin Press Release.23.01.2024.6.Gardner,J.Lilly sales surge on obesity,diabetes drug demand.Biopharma Dive.06.02.2024.7.Investor Update.Ad hoc announcement pursuant to Art.53 LR.Roche Press Release.01.02.2024.8.Amgen reports fourth quarter and full year 2023 financial results.Amgen Press Release.06.02.2024.声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 红色转载开白 | 马老师 18996384680（同微信）商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

专利到期生物类似药财报并购

2024-02-21

·BioSpace

Discover this new generic drug in the PERINDOPRIL range

MONTREAL, Feb. 21, 2024 /CNW/ - Pharmascience Canada is proud to announce the launch of pms-PERINDOPRIL-AMLODIPINE (perindopril arginine and amlodipine), a drug indicated for the treatment of mild to moderate essential hypertension in adults aged 18 to 65 for whom combination therapy is appropriate. This oral treatment contains two medicines, perindopril arginine and amlodipine. They work together to control the blood pressure. pms-PERINDOPRIL-AMLODIPINE are available in bottles of 100 tablets and comes in the following dosage forms: 3.5 mg / 2.5 mg (this treatment is indicated for initial therapy in patients with mild to moderate essential hypertension.) 7 mg / 5 mg 14 mg / 10 mg This medication is a generic equivalent of Viacoram MD1. pms-PERINDOPRIL-AMLODIPINE tablets are available at affordable prices. « We are excited to introduce Perindopril Amlodipine to the Canadian market, as it reflects our mission to improve the health and quality of life of Canadians through innovative and high-quality products, » said Mike Dutton, Vice-President and General Manager of Pharmascience Canada. « Perindopril Amlodipine is manufactured in our Canadian facility which is another example of how we leverage our expertise and capabilities to deliver value to our customers and patients. » ABOUT PHARMASCIENCE INC. Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research & Development (R&D) investors in 2022, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada. Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2024, the company was awarded Great Place to Work certification for the third year running. PRVIACORAM®1 is a registered trademark owned by Servier Canada Inc. For product information, please contact Pharmascience's Medical Information Department at 1-888-550-6060. SOURCE Pharmascience Inc.

上市批准

2023-08-22

·PRNewswire

RedDress Receives Vizient Contract for Advanced Wound Care Solution ActiGraft PRO

Medicare and Medicare Advantage reimbursement status was recently obtained for ActiGraft PRO, enabling the wound care industry's most advanced whole-blood wound care solution to be purchased by wound care centers and practitioners nationally TEL AVIV, Israel and JACKSONVILLE, Fla., Aug. 22, 2023 /PRNewswire/ -- RedDress, developers of the ActiGraft PRO system, a personalized and autologous wound care solution created from patients' own whole blood, today announced that its ActiGraft PRO product is now available through Vizient, the nation's largest provider-driven healthcare performance improvement company. RedDress secured an Innovative Technology contract with Vizient in October 2022 and G-Code reimbursement status from Medicare and Medicare Advantage in July 2023. The agreement with Vizient now provides increased access to ActiGraft PRO to Vizient's customer base, which comprises academic medical centers, community hospitals, integrated health delivery networks and non-acute health care providers. Vizient's Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient's Innovative Technology Program. Vizient customer-led councils identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety or improve business operations of healthcare organizations. "We are excited for the momentum we are experiencing since obtaining Medicare reimbursement status and are thrilled to make ActiGraft PRO now available to wound care specialists nationally through Vizient," said Alon Kushnir, CEO and Co-Founder of RedDress. "Autologous, blood-based therapies are the future of wound care, and with ActiGraft PRO as the leading solution in the category, our contract with Vizient will significantly increase access to advanced wound care for patients and healthcare providers." The ActiGraft PRO system is an autologous, point-of-care wound management solution created from patient's whole blood. Once applied, the blood clot serves as a protective covering and optimizes the body's own healing potential. ActiGraft PRO is designed to jump-start wound healing and to meet the needs of today's high-volume practices and centers, offering practitioners a wound healing solution that delivers a quick, easy, and clean procedure. Applied directly to the wound surface, the ActiGraft PRO blood clot is created at the patient's bedside in under five minutes by mixing fresh whole blood with our proprietary coagulation powder. ActiGraft PRO contains whole blood cells including white cells, red cells, plasma, platelets, and fibrin, in the optimal concentration required in the wound healing process. Once applied, ActiGraft PRO reignites the healing cascade, serving as a protective covering that supports wound healing processes which occur naturally in the body. While reimbursement for ActiGraft PRO currently applies only to diabetic patients with lower extremity, non-pressure injury chronic wounds, ActiGraft PRO can be used for a wide variety of chronic wounds including but not limited to: Diabetic and Neuropathic Ulcers, Venous Ulcers, Traumatic Wounds, Post-Surgical Wounds, Skin Tears and Surgical Wounds. Since RedDress received FDA clearance and a CE Mark in 2020, ActiGraft has helped over 6,000 patients across the spectrum of healthcare facilities in the United States and 30 other countries. Disclaimer: The information provided shall not be constructed as a statement, promise, or guarantee that reimbursement will be received. Reimbursement requirements are subject to change at any time. Check with your local payer regularly. About RedDress RedDress is the leading provider of personalized and autologous wound management solutions created from patients own blood. The company's suite of ActiGraft products are transforming wound care, treating a wide variety of chronic wounds including diabetic and neuropathic ulcers, venous ulcers, pressure injuries, traumatic wounds, post-surgical wounds, skin tears, surgical wounds and more. ActiGraft PRO, the company's most advanced wound care product is exclusively available in the US. The ActiGraft wound care system is available internationally only, already commercially available in 30 countries across five continents. RedDress is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Jacksonville, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, RedDress is dedicated to using its whole-blood technology to find solutions to other human ailments. For more information, please visit SOURCE RedDress

100 项与苯磺酸氨氯地平/精氨酸培哚普利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C09BB04	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	马来西亚	Les Laboratoires Servier SAS	2010-05-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	美国	Symplmed Pharmaceuticals LLC	2012-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2016	N/A	高血压	102	Perindopril/amlodipine combination	糧觸蓋廠網餘醖醖鬱製(蓋顧網醖製衊夢壓鑰遞) = 衊製網醖廠鬱夢觸鏇積鏇繭蓋遞襯鑰糧醖衊齋 (醖蓋齋艱壓齋鹹窪構願 )	-	2016-12-07
POTENTIAL study (ESC2016)	N/A	-	459	FDC perindopril arginine/amlodipine	範齋築衊網願製鏇獵構(網鑰積衊鹹醖願蓋鹽憲) = 鹽憲餘齋願繭夢簾選壓廠壓遞廠襯艱廠壓網網 (鬱鏇選製蓋鏇鏇齋鹽製 )	-	2016-08-28
				Free combinations of lisinopril + amlodipine	範齋築衊網願製鏇獵構(網鑰積衊鹹醖願蓋鹽憲) = 網夢獵選遞醖窪餘憲網廠壓遞廠襯艱廠壓網網 (鬱鏇選製蓋鏇鏇齋鹽製 )
NCT01556997 (CTgov)	临床3期	原发性高血压	837	XOMA 985 (XOMA 985)	醖顧衊選願淵憲鏇窪繭(襯繭構鹹衊網襯壓壓襯) = 願構鹹繭選鑰繭範艱製蓋獵製蓋淵醖齋壓觸夢 (遞築艱夢鏇壓齋繭夢淵, 醖艱範簾廠簾顧廠夢網 ~ 衊膚網鬱選鹽廠範淵壓) 更多	-	2015-08-25
				Amlodipine Besylate (Amlodipine Besylate (AMLb))	醖顧衊選願淵憲鏇窪繭(襯繭構鹹衊網襯壓壓襯) = 餘醖齋鬱觸顧憲網餘糧蓋獵製蓋淵醖齋壓觸夢 (遞築艱夢鏇壓齋繭夢淵, 糧製簾廠襯窪壓觸鬱簾 ~ 糧襯鏇壓鑰遞鬱網積鏇) 更多